Rhumbline Advisers boosted its holdings in shares of Atara Biotherapeutics, Inc. (NASDAQ: ATRA – Get Rating) by 1.6% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 128,089 shares of the biotechnology company stock after buying an additional 2,052 shares during the quarter. Rhumbline Advisers owned approximately 0.14% of Atara Biotherapeutics worth $ 2,019,000 as of its most recent SEC filing.
A number of other hedge funds have also modified their holdings of the stock. DekaBank Deutsche Girozentrale increased its holdings in Atara Biotherapeutics by 2.9% during the fourth quarter. DekaBank Deutsche Girozentrale now owns 28,400 shares of the biotechnology company stock valued at $ 476,000 after buying an additional 800 shares during the period. Teacher Retirement System of Texas boosted its stake in Atara Biotherapeutics by 19.8% in the fourth quarter. Teacher Retirement System of Texas now owns 13,719 shares of the biotechnology company stock valued at $ 216,000 after acquiring an additional 2,268 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. boosted its stake in Atara Biotherapeutics by 15.7% in the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 18,477 shares of the biotechnology company stock valued at $ 291,000 after acquiring an additional 2,513 shares in the last quarter. Macquarie Group Ltd. lifted its stake in shares of Atara Biotherapeutics by 326.1% during the third quarter. Macquarie Group Ltd. now owns 3,311 shares of the biotechnology company stock worth $ 59,000 after buying an additional 2,534 shares during the period. Finally, ProShare Advisors LLC lifted its stake in shares of Atara Biotherapeutics by 9.5% during the fourth quarter. ProShare Advisors LLC now owns 31,414 shares of the biotechnology company stock worth $ 495,000 after buying an additional 2,717 shares during the period.
In other news, CFO Utpal Koppikar sold 5,582 shares of Atara Biotherapeutics stock in a transaction on Tuesday, May 17th. The stock was sold at an average price of $ 5.32, for a total value of $ 29,696.24. Following the completion of the sale, the chief financial officer now directly owns 207,592 shares of the company stock, valued at $ 1,104,389.44. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Pascal Touchon sold 13,913 shares of Atara Biotherapeutics stock in a transaction on Tuesday, May 17th. The shares were sold at an average price of $ 5.32, for a total value of $ 74,017.16. Following the completion of the sale, the chief executive officer now directly owns 486,313 shares of the company stock, valued at $ 2,587,185.16. The disclosure for this sale can be found here. In the last three months, insiders have sold 26,591 shares of company stock valued at $ 141,464. 4.00% of the stock is owned by insiders.
NASDAQ: ATRA opened at $ 5.14 on Friday. Atara Biotherapeutics, Inc. has a one year low of $ 4.61 and a one year high of $ 20.04. The stock has a market cap of $ 480.13 million, a PE ratio of -1.41 and a beta of 1.94. The stock has a 50 day moving average price of $ 6.89 and a 200 day moving average price of $ 11.78.
Atara Biotherapeutics (NASDAQ: ATRA – Get Rating) last posted its earnings results on Thursday, May 5th. The biotechnology company reported ($ 0.87) earnings per share (EPS) for the quarter, topping the consensus estimate of ($ 0.98) by $ 0.11. Atara Biotherapeutics had a negative return on equity of 122.18% and a negative net margin of 1,451.79%. During the same quarter in the previous year, the business earned ($ 0.86) earnings per share. As a group, sell-side analysts forecast that Atara Biotherapeutics, Inc. will post -3.45 EPS for the current year.
Several equities research analysts have recently commented on the stock. Citigroup downgraded shares of Atara Biotherapeutics from a “buy” rating to a “neutral” rating and lowered their price objective for the stock from $ 15.00 to $ 8.00 in a research note on Monday, May 9th. JPMorgan Chase & Co. reduced their target price on shares of Atara Biotherapeutics from $ 27.00 to $ 22.00 and set an “overweight” rating for the company in a report on Monday, March 28th. Canaccord Genuity Group reduced their target price on shares of Atara Biotherapeutics from $ 78.00 to $ 67.00 in a report on Tuesday, March 1st. StockNews.com cut shares of Atara Biotherapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, May 17th. Finally, The Goldman Sachs Group cut their target price on shares of Atara Biotherapeutics from $ 5.00 to $ 4.00 and set a “sell” rating for the company in a report on Tuesday, May 24th. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating and four have given a buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $ 26.88.
About Atara Biotherapeutics: (Get Rating)
Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as hematologic and solid tumors, including nasopharyngeal carcinoma.
Want to see what other hedge funds are holding ATRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Atara Biotherapeutics, Inc. (NASDAQ: ATRA – Get Rating).
Receive News & Ratings for Atara Biotherapeutics Daily: – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Atara Biotherapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.